A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Name: A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Creator: Vivli
Published: 2024-10-10T20:51:55+08:00

DataCite Commons2025-04-01 更新2026-05-07 收录

血液肿瘤新药临床试验

药代动力学与药效学评估

数据链接：

https://search.vivli.org/doiLanding/studies/PR00010636/isLanding 数据链接链接失效反馈

官方服务：

资源简介：

The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.

提供机构：

Vivli

创建时间：

2024-10-10